Roche beginnt mit dem Bau seines neuen Diagnostik-Produktionszentrums in Penzberg: Auf der rund 7,5 Hektar großen, für die Bebauung bereits vorbereiteten Erweiterungsfläche im Norden des Werks entsteht eines der modernsten Produktionsgebäude in Europa zur Herstellung von Einsatzstoffen für eine Vielzahl von diagnostischen Tests. Paul Wiggermann, Werkleiter von Roche in Penzberg, vollzog den symbolischen Spatenstich zusammen mit Alexander Dobrindt, Mitglied des Bundestags (MdB) und Vorsitzender der CSU im Bundestag, sowie weiteren Vertreter der Lokalpolitik und von Roche. Mit einer Investitionssumme von rund 600 Millionen Euro ist der Neubau die bislang größte Einzelinvestition des Unternehmens in Bayern und in Deutschland. Bis 2028 soll der Betrieb im neuen Gebäude aufgenommen werden.

In Hessen werden viele Apotheken am Donnerstag und Freitag dieser Woche geschlossen bleiben. Der Hessische Apothekerverband (HAV) hat zu diesem Protest gegen die Reformpläne von Bundesgesundheitsminister Karl Lauterbach (SPD) aufgerufen. Der HAV-Vorsitzende Seyfarth bezeichnete den vor wenigen Tagen vorgestellten Entwurf als einen „Todesstoß für den gesamten Berufsstand“ und betonte, dass dieser die „schlimmsten Erwartungen noch […] Apotheken zwei Tage geschlossen

Der Vorsitzende der Geschäftsleitung der Localmed & City Notfall AG, Daniel Galli, hat sich entschieden, das Unternehmen per Ende September 2024 zu verlassen, um beruflich kürzerzutreten und sich neu zu orientieren. Unter seiner Führung ist die Unternehmung von vier auf acht Praxen angewachsen, der Umsatz wie der Mitarbeiterbestand haben sich dabei verdoppelt. […] Wechsel in der Führung der Localmed & City Notfall AG

Semaglutide 1 mg demonstrated a statistically significant and superior reduction of 24% in the risk of kidney disease-related events vs. placebo in adults with type 2 diabetes and chronic kidney disease.Based on FLOW trial data, Novo Nordisk submitted a label extension application for Ozempic®, which has been accepted for review by the FDA. Novo Nordisk today presented the full results from FLOW, its phase 3b kidney outcomes trial investigating the effects of once-weekly injectable semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease (CKD), at the 84th Annual Scientific Sessions of the American Diabetes Association (ADA). The double-blind, randomized, placebo-controlled trial, which enrolled 3,533 people with type 2 diabetes and CKD, achieved its primary endpoint, with semaglutide 1 mg demonstrating a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared… 

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, presents the key results of the first Phase 3 clinical trial of mazdutide in Chinese adults with overweight or obesity (GLORY-1) at the ADA Scientific Sessions 2024. The primary endpoints and all key secondary endpoints of GLORY-1 were met, reconfirming the unique advantages of the GLP-1R/GCGR dual agonist Mazdutide (Innovent R&D code: IBI362) is a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist. By activating GLP-1R, it reduces appetite and delays gastric emptying, thereby achieving weight loss. At the same time, through activation of GCGR, it increases energy expenditure, enhances fatty acid oxidation and lipolysis, and reduces liver fat. The results of the GLORY-1 study demonstrated that… 

BND-35 is a Novel and Unique Anti-ILT3/LILRB4 Antibody for Remodeling the Tumor Microenvironment. BND-35-001 trial includes unique combination arms with anti-EGFR (cetuximab) and anti-PD-1/PD-L1, in selected indications Biond Biologics Ltd. („Biond“ or the „Company“), a private clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform for the intracellular delivery of biologics, today announced that the first patient has been dosed in a first-in-human clinical trial testing BND-35, a humanized ILT3/LILRB4 antagonist antibody. The first patient was administered BND-35 as a monotherapy at the Institute of Oncology, Davidoff Center, Rabin Medical Center, Israel, one of the six Israel and US trial study sites. The phase 1, open-label, dose escalation study aims to explore the safety, tolerability, anti-tumor activity, pharmacokinetics and exploratory biomarkers for BND-35 as a monotherapy and in combination with two approved drugs, a PD-1/PD-L1 inhibitor or the… 

BND-35 is a Novel and Unique Anti-ILT3/LILRB4 Antibody for Remodeling the Tumor Microenvironment. BND-35-001 trial includes unique combination arms with anti-EGFR (cetuximab) and anti-PD-1/PD-L1, in selected indications Biond Biologics Ltd. („Biond“ or the „Company“), a private clinical-stage biopharmaceutical company developing novel immunotherapies for cancer and a platform for the intracellular delivery of biologics, today announced that the first patient has been dosed in a first-in-human clinical trial testing BND-35, a humanized ILT3/LILRB4 antagonist antibody. The first patient was administered BND-35 as a monotherapy at the Institute of Oncology, Davidoff Center, Rabin Medical Center, Israel, one of the six Israel and US trial study sites. The phase 1, open-label, dose escalation study aims to explore the safety, tolerability, anti-tumor activity, pharmacokinetics and exploratory biomarkers for BND-35 as a monotherapy and in combination with two approved drugs, a PD-1/PD-L1 inhibitor or the… 

Cordella, which consists of the now PMA-approved Cordella PA Sensor and commercial Cordella™ HF System, enables comprehensive heart failure management in the home using pulmonary artery (PA) pressure, a leading indicator of congestion, and non-invasive vital sign data to improve care decisions.Backed by definitive clinical evidence from the PROACTIVE-HF pivotal trial, the company is planning a U.S. launch of Cordella this year.